Emerging Prostate and Brain MRI AI Platform Gets FDA Nod
In addition to a previously FDA-cleared brain magnetic resonance imaging (MRI) module, the Advantis Platform features an artificial intelligence-powered prostate MRI module that offers simultaneous viewing of conventional and advanced sequences, and reportedly generates automated PI-RADS assessments.
The Food and Drug Administration (FDA) has reportedly granted 510(k) clearance to the Advantis Platform (Advantis Medical Imaging), which offers artificial intelligence-enabled modules for multiparametric prostate MRI as well as brain MRI analysis.
The Advantis Prostate module streamlines radiology workflows with automated diffusion-weighted imaging (DWI) and dynamic contrast-enhanced (DCE) MRI maps, and simultaneous viewing of advanced and conventional sequences in one viewer, according to Advantis Medical Imaging. The company adds that the Advantis Prostate module provides automated PI-RADS reporting with one click.
Images courtesy of Advantis Medical Imaging.
Advantis Medical Imaging said the Advantis Brain module (which previously garnered FDA 510(k) clearance under the name Brainance MD) offers a variety of features including automated processing of dynamic susceptibility contrast (DSC) MRI perfusion scans with expedient exporting of maps and key findings to the existing PACS system. Another benefit of Advantis Brain is fully automated tractography with single-click fiber tracking on diffusion tensor imaging (DTI), according to the company.
“This latest FDA clearance is a testament to our commitment to delivering innovative solutions that streamline workflows and provide clinicians with reliable, accessible and efficient software tools,” noted Zoi Giavri, the chief product office for Advantis Medical Imaging. “Our recent integration of the multiparametric prostate MRI module in our software suite, Advantis Platform, complements the existing brain MRI module while both of them enable healthcare professions to more easily extract meaningful information from MRIs.”
(Editor’s note: For related content, see “Can Explainable AI Enhance Diagnosis and PI-RADS Classification of Prostate Cancer on MRI?” and “FDA Clears New AI Software for MRI Detection of Prostate Cancer.”
New bpMRI Study Suggests AI Offers Comparable Results to Radiologists for PCa Detection
April 15th 2025Demonstrating no significant difference with radiologist detection of clinically significant prostate cancer (csPCa), a biparametric MRI-based AI model provided an 88.4 percent sensitivity rate in a recent study.
Expanded FDA Approval Allows Use of Pluvicto Prior to Chemotherapy in Patients with mCRPC
March 28th 2025Recent research demonstrated a 59 percent reduced risk of progression or death with the radioligand therapy Pluvicto in comparison to a change of androgen receptor pathway inhibitor (ARPI) for patients with metastatic castration-resistant prostate cancer (mCRPC).
Study: Monitoring of Prostate MRI Exams Could Lead to 75 Percent Reduction of Gadolinium Contrast
March 17th 2025While DCE MRI was deemed helpful in over 67 percent of cases in which it was used, researchers found that monitored prostate MRI exams, which facilitated a 75 percent reduction of DCE MRI sequences, had comparable sensitivity for prostate cancer as non-monitored exams.
